계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Protagonist Therapeutics
company
About
Protagonist Therapeutics develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies.
- 101 - 250
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1.34M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2001
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
$56.79M
Protagonist Therapeutics has raised a total of
$56.79M
in funding over 2 rounds. Their latest funding was raised on
Sep 6, 2018 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 6, 2018 | Grant | $1.45M | 1 |
National Institutes of Health
|
— | Detail |
| May 24, 2017 | Grant | $1.34M | 1 |
National Institutes of Health
|
— | Detail |
| Jul 16, 2015 | Series C | $40M | 2 | — | — | Detail |
| Jun 4, 2013 | Series B | $14M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
2
3
Protagonist Therapeutics is funded by 3 investors.
National Institutes of Health
and Pharmstandard International
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
|
|
— | Series C |
Inbio Ventures
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
